House Bill 1166 makes a direct appropriation from Indiana’s state general fund to the therapeutic psilocybin research fund. The bill provides $300,000 for fiscal year 2025-2026 and another $300,000 for fiscal year 2026-2027, for a total of $600,000, to be used by the Division of Mental Health and Addiction for the purposes of the fund. The appropriation is temporary and the section expires on July 1, 2027.
The bill does not create a new regulatory program or amend existing code provisions beyond funding the already-established therapeutic psilocybin research fund. Its practical effect is to supply state money for research-related activities connected to psilocybin and mental health treatment, potentially supporting studies, administration, or other authorized uses under the fund’s existing statutory framework.
Impact
HB 1166 affects state finances rather than substantive criminal, health, or controlled-substances law. It allocates general fund dollars to an existing noncode therapeutic psilocybin research fund, directing the Division of Mental Health and Addiction to use the money for the fund’s purposes. Because the bill is an appropriation measure, its legal impact is to authorize spending for two fiscal years and then sunset the appropriation section, without changing the underlying statutory structure of the fund.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the available context suggests a straightforward, policy-oriented measure focused on funding research rather than a highly contested proposal. The caption and structure indicate support for exploring therapeutic psilocybin research through state investment, but there is no recorded debate in the provided materials to show broader agreement or opposition. Overall sentiment appears neutral to mildly supportive, with the main emphasis on providing resources for mental health-related research.
Contention
No committee transcript or vote record is provided, so specific points of contention cannot be identified from the available materials. In general, bills involving psilocybin research can raise concerns about the use of public funds, the medical legitimacy of psychedelic therapies, and the relationship between research funding and broader drug policy. Potential supporters would likely include advocates for mental health research and alternative treatments, while skeptics may question whether state general fund dollars should be used for this purpose.